Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge

Title

Sanofi Approaches Blockbuster Status with Altuviiio as Dupixent Sales Continue Rapid Growth

Keywords

Sanofi
Altuviiio
Blockbuster drug
Dupixent
Pharmaceutical sales
Q1 2025 earnings
Pharma launches
Market share
FDA approval
Immunology

Key Facts

Altuviiio, Sanofi’s next-generation hemophilia A therapy, is on track to achieve blockbuster status (over $1 billion in annual sales) in 2025 if it maintains its current sales momentum after receiving FDA approval in 20234.
In Q1 2025, pharmaceutical launches, largely driven by Altuviiio, reached €0.8 billion in sales, marking a 43.8% increase year-on-year1 2 5.
Dupixent, a blockbuster drug for inflammatory conditions, reported sales of €3.5 billion in Q1 2025—representing a 20.3% growth compared to the previous year1 5.
Sanofi reported overall Q1 2025 sales growth of 9.7% at constant exchange rates, surpassing analyst expectations and reflecting strong performance across its innovative portfolio1 3.
The company’s robust pipeline continued to deliver, with six regulatory approvals in immunology, rare diseases, and oncology during the period1 5.

- Product conversions:
Eloctate sales dropped by 20.9% as patients switched to Altuviiio in both the US and Japan, underscoring Altuviiio's commercial momentum2.

Sanofi’s business EPS for Q1 2025 was €1.79, up 15.7% year-over-year at constant exchange rates1 5.
The company's R&D spend increased by 6.9% to €1.8 billion, reflecting continued investment in innovation and pipeline expansion1 5.